Journal
AMYOTROPHIC LATERAL SCLEROSIS
Volume 10, Issue 2, Pages 63-73Publisher
INFORMA HEALTHCARE
DOI: 10.1080/17482960802160370
Keywords
Amyotrophic lateral sclerosis; insulin-like growth factor-I; treatment
Categories
Funding
- A. Alfred Taubman Medical Research Institute
- Neurology Research and Discovery
- NIH [T32 NS007222-26]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007222] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects both upper and lower motor neurons (MN) resulting in weakness, paralysis and subsequent death. Insulin-like growth factor-I (IGF-I) is a potent neurotrophic factor that has neuroprotective properties in the central and peripheral nervous systems. Due to the efficacy of IGF-I in the treatment of other diseases and its ability to promote neuronal survival, IGF-I is being extensively studied in ALS therapeutic trials. This review covers in vitro and in vivo studies examining the efficacy of IGF-I in ALS model systems and also addresses the mechanisms by which IGF-I asserts its effects in these models, the status of the IGF-I system in ALS patients, results of clinical trials, and the need for the development of better delivery mechanisms to maximize IGF-I efficacy. The knowledge obtained from these studies suggests that IGF-I has the potential to be a safe and efficacious therapy for ALS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available